ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
CH3OC10H6CH(CH3)CO2H
CAS番号:
分子量:
230.26
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3591068
InChI key
CMWTZPSULFXXJA-VIFPVBQESA-N
SMILES string
COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O
InChI
1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
grade
pharmaceutical primary standard
API family
naproxen
manufacturer/tradename
EDQM
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
mp
152-154 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PTGS1(5742), PTGS2(5743)
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Naproxen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
非選択的なシクロオキシゲナーゼ(COX-1およびCOX-2)阻害剤です。
Packaging
この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。
Other Notes
Sales restrictions may apply.
signalword
Warning
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
保管分類
11 - Combustible Solids
wgk
WGK 3
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
N0250000-1EA: + N0250000: + N0250000-100MG:
jan
D Haupt et al.
Journal of biochemical and biophysical methods, 25(4), 273-284 (1992-12-01)
A column-switching system for fast determination of (R)- and (S)-naproxen in liver microsomes has been developed. The centrifuged sample was injected directly onto a pre-column with octadecylcoated silica. The retained analytes were then directed to an alpha 1-AGP column using
Marta L Capone et al.
Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)
We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5
Jiayang Li et al.
Journal of the American Chemical Society, 135(2), 542-545 (2012-11-10)
As systemically used therapeutics for treating acute or chronic pains or inflammations, nonsteroidal anti-inflammatory drugs (NSAIDs) also associate with the adverse gastrointestinal and renal effects and cardiovascular risks. Thus, it is beneficial to develop topical gels that selectively inhibit cyclooxygenase-2
J Rossat et al.
Clinical pharmacology and therapeutics, 66(1), 76-84 (1999-08-03)
To compare the renal hemodynamic and tubular effects of celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2) to those of naproxen, a nonselective inhibitor of cyclooxygenases in salt-depleted subjects. Forty subjects were randomized into four parallel groups to receive 200 mg
J Sieper et al.
Annals of the rheumatic diseases, 73(1), 101-107 (2013-05-23)
To assess whether combination therapy with infliximab (IFX) plus nonsteroidal anti-inflammatory drugs (NSAIDs) is superior to NSAID monotherapy for reaching Assessment of SpondyloArthritis international Society (ASAS) partial remission in patients with early, active axial spondyloarthritis (SpA) who were naïve to
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）